INTO | Inorganic therapeutic nanoparticles for osteoporosis

Summary
The aim of the proposed interdisciplinary project is to design, make and test novel nanoparticles that will have direct and rapid impact in osteoporosis. The unique aspect of these injectable nanoparticles is that they will deliver active therapy locally, to where it is needed, and that the cargo is not a conventional drug, but a sustained delivery of a combination of active inorganic cations and rare earth nanoparticles. Certain cations can promote bone growth and inhibit resorption and nanoceria can scavenge free radicals that would otherwise accelerate osteoporosis. Systemic concentrations of active agents will be much smaller that caused by taking oral drugs. Delivery will be sustained because it is controlled by the dissolution rate of biodegradable mesoporous silica nanoparticles, which will improve over biodegradable polymer capsules that often deliver a burst release of their drug cargo. Beyond the project, long-term impact could include slowing metastasis of tumours into bone (e.g. breast cancer to the sternum). The biodegradable mesoporous silica nanoparticles will be synthesised by sol-gel, while the nanoceria will be synthesized by co-precipitation method and microwave treatment and entrapped within the silica network. Key aspects will be: incorporation of active ions and nanoceria within monodispersed silica nanoparticles of controlled size; ensuring the particles remain dispersed in body fluid (control of surface chemistry); testing efficacy in cell co-culture (uptake and cell stimulation) and investigating the effect of the presence of the particles on immune cells. The effect of process variables on composition, particle size, bioactivity, degradation rate, radical scavenger ability and the cellular response will be investigated.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/705592
Start date: 01-06-2016
End date: 31-05-2018
Total budget - Public funding: 183 454,80 Euro - 183 454,00 Euro
Cordis data

Original description

The aim of the proposed interdisciplinary project is to design, make and test novel nanoparticles that will have direct and rapid impact in osteoporosis. The unique aspect of these injectable nanoparticles is that they will deliver active therapy locally, to where it is needed, and that the cargo is not a conventional drug, but a sustained delivery of a combination of active inorganic cations and rare earth nanoparticles. Certain cations can promote bone growth and inhibit resorption and nanoceria can scavenge free radicals that would otherwise accelerate osteoporosis. Systemic concentrations of active agents will be much smaller that caused by taking oral drugs. Delivery will be sustained because it is controlled by the dissolution rate of biodegradable mesoporous silica nanoparticles, which will improve over biodegradable polymer capsules that often deliver a burst release of their drug cargo. Beyond the project, long-term impact could include slowing metastasis of tumours into bone (e.g. breast cancer to the sternum). The biodegradable mesoporous silica nanoparticles will be synthesised by sol-gel, while the nanoceria will be synthesized by co-precipitation method and microwave treatment and entrapped within the silica network. Key aspects will be: incorporation of active ions and nanoceria within monodispersed silica nanoparticles of controlled size; ensuring the particles remain dispersed in body fluid (control of surface chemistry); testing efficacy in cell co-culture (uptake and cell stimulation) and investigating the effect of the presence of the particles on immune cells. The effect of process variables on composition, particle size, bioactivity, degradation rate, radical scavenger ability and the cellular response will be investigated.

Status

CLOSED

Call topic

MSCA-IF-2015-EF

Update Date

28-04-2024
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.1. EXCELLENT SCIENCE
H2020-EU.1.3. EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions (MSCA)
H2020-EU.1.3.2. Nurturing excellence by means of cross-border and cross-sector mobility
H2020-MSCA-IF-2015
MSCA-IF-2015-EF Marie Skłodowska-Curie Individual Fellowships (IF-EF)